Federal PBM Compensation Shifts: Early CAA 2026 Considerations

The Consolidated Appropriations Act, 2026 (CAA 2026) introduces the most significant federal restructuring of pharmacy benefit manager (PBM) compensation to date. Effective January 2028, the act restructures Medicare Part D by effectively eliminating spread pricing, mandating the full pass-through of manufacturer remuneration, restricting PBM revenue to bona fide service fees delinked from drug prices and codifying "any willing pharmacy" network inclusivity. Similar mandates apply under the Employee Retirement Income Security Act of 1974 (ERISA) for employer-sponsored plans, though they are primarily subject to mandatory pass‑through and fiduciary reasonableness standards rather than explicit statutory delinking of service fees. Reforms to the Internal Revenue Code of 1986, the Public Health Service Act, Medicare, and ERISA aim to improve transparency and auditing for patients, payers, and the federal government while reducing incentives tied to high list prices. This transparency redefines PBM-payer engagement, reconfiguring the PBM's role within the drug supply chain. Furthermore, the CAA 2026 redistributes PBM profits to Medicare and ERISA plans, shifting the emphasis from rebate maximization to net cost savings and transferring greater financial risk to plan sponsors. This commentary examines the structural implications of these reforms for managed care pharmacy, including emerging challenges related to incentive alignment, administrative burden, and formulary design. Importantly, these implications represent early interpretations of potential downstream effects rather than finalized regulatory outcomes. Early evidence suggests that while the CAA 2026 enhances accountability, it may also introduce new distortions in pricing strategies. Managed care organizations will likely need to adapt to a data-intensive, plan-centric model of oversight as these reforms continue to evolve.